What Oxitan Treats: Main Uses and Benefits

The core purpose of Oxitan is the systemic management of malignant conditions, primarily concerning cancers of the digestive system. The medication is used in the clinical context of advanced colorectal cancer and for adjuvant treatment following surgery in patients with Stage III colon cancer. It is also utilized for managing conditions that include specific gastrointestinal malignancies like gastric, pancreatic, and biliary tract cancers.

The medicine is applied with the therapeutic objective of disease management in scenarios marked by temporary physiological imbalance associated with active cell proliferation. This intervention may play a role in managing the risk of recurrence after surgery, and it may assist with maintaining comfort and general well-being in cases of widespread tumors.

“This medicine is often applied within structured treatment plans designed to support general well-being during symptomatic phases.”

Quick Fact: Supportive Management in Malignant Conditions

Oxitan is used to help manage conditions characterized by periods of heightened symptoms stemming from uncontrolled malignant growth, and may assist with maintaining functional stability by managing symptoms that interfere with daily comfort.

Oxitan (Oxaliplatin) is a platinum-based chemotherapy drug primarily indicated for the treatment of colorectal cancer. It is typically administered as part of a combination regimen.

---

Who Can Use Oxitan?

Oxitan is used by adult patients diagnosed with:

• Advanced colorectal cancer (metastatic).
• Stage III colon cancer following complete resection of the primary tumor (adjuvant therapy).

Use in elderly patients requires careful monitoring, but no specific dose adjustment is usually necessary unless toxicities occur.

---

Who Cannot Use Oxitan? (Contraindications)

Oxitan is generally contraindicated (should not be used) in patients with the following conditions:

Condition
A known history of hypersensitivity or allergy to oxaliplatin or other platinum-containing compounds (e.g., cisplatin, carboplatin).
Severe renal impairment (severely impaired kidney function), generally defined as creatinine clearance less than 30 mL/ min.
Severe myelosuppression (low blood cell counts) before the first course, specifically baseline neutrophils < 2 imes 10^9/ L and/or platelet count < 100 imes 10^9/ L.
Pre-existing peripheral sensory neuropathy with functional impairment (e.g., difficulty with daily tasks like buttoning clothes).
Pregnancy or breastfeeding, as the drug can cause fetal harm and is unsafe for the nursing infant.

Oxitan is not recommended for use in children and adolescents under 18 years of age due to a lack of established safety and efficacy data.

Interactions with other medicines and products

The interaction profile for Oxitan (Oxaliplatin) is primarily defined by pharmacodynamic risks and mandatory procedural constraints, rather than common metabolic interactions. Official regulatory documents state that clinically relevant interactions mediated by Cytochrome P450 (CYP) enzymes are not anticipated, as Oxaliplatin is neither a substrate nor an inhibitor of these pathways.

---

Interaction Domain	Documented Restriction or Outcome
Immunological Risk	Co-administration with Live Attenuated Vaccines is restricted due to the potential for the medicine's immunosuppressive effects to cause severe systemic disease.
Pharmacodynamic Risk	Concurrent use with other Immunosuppressants carries the risk of additive immunosuppression and heightened susceptibility to infection.
Chemical Incompatibility	A mandatory physical separation is required from Aluminum-Containing Materials (e.g., needles, catheters). Contact with aluminum causes chemical incompatibility, leading to precipitation and inactivation of the active substance.

---

Official information also addresses exposure management in specific populations. Renal Impairment is explicitly noted as a condition that reduces the clearance of the active platinum derivative, leading to formally increased systemic exposure and a heightened risk of toxicity. The regulatory data thus structures the interaction profile around immunological restrictions and mandatory chemical incompatibility rules.

How Oxitan Works: Mechanism of Action

Oxitan (Oxaliplatin) exerts its influence through a sequence of precise pharmacodynamic events, affecting both cell proliferation control and nerve function.

---

Targeted DNA Cross-linking and Cellular Destruction

The primary mechanism involves the platinum complex binding directly and covalently to the Genomic DNA within rapidly dividing cells, predominantly forming bulky intra-strand cross-links at Guanine sites. This functional DNA damage physically blocks the cell's ability to replicate its genetic material or transcribe genes, which activates the DNA Damage Response (DDR) pathway. This cascade ultimately forces the cell to undergo programmed cell death (apoptosis), resulting in the physiological consequence of a reduction in the population of rapidly dividing cells.

---

Modulation of Peripheral Nerve Excitability

A secondary, yet important, mechanistic domain is the compound’s direct or indirect influence on the Voltage-Gated Sodium Channels ( Na^+ channels) located on peripheral sensory neurons. By modulating these channels, the drug alters the nerve's signal transmission properties, lowering its activation threshold and leading to neuronal hyperexcitability.

---

Mechanistic Synergy via Enzyme Inhibition

When used in combination with other agents, Oxaliplatin functions as an inhibitor of the enzyme Dihydropyrimidine Dehydrogenase (DPD), the main enzyme responsible for breaking down co-administered fluoropyrimidines. This inhibition reduces the metabolic clearance of the co-agent, increasing its cellular concentration and half-life, thereby leading to mechanistic synergy due to increased duration and concentration of the co-agent, which contributes to the cytotoxic action.

How Oxitan (Oxaliplatin) is Used in Clinical Practice

Oxitan administration is governed by strictly defined protocols established in official prescribing information to ensure standardized use in systemic malignant disease management. It is consistently used as part of a combination chemotherapy regimen alongside fluorouracil and leucovorin.

---

Official Administration and Dosing Principles

Oxitan is strictly administered as an intravenous (IV) infusion under the supervision of a physician experienced in chemotherapy. There are no approved oral or other forms of administration.

Usage Parameter	Regulatory Guideline
Standard Dose	85 mg/m^2 Body Surface Area (BSA)
Frequency	Once every two weeks (a 14-day cycle)
Infusion Duration	Typically 120 minutes (2 hours)
Timing in Regimen	The Oxaliplatin infusion must precede the fluorouracil/leucovorin administration
Adjuvant Duration Limit	A maximum of 12 cycles (approximately 6 months)

---

Preparation and Population Adjustments

Preparation for administration requires specific procedures to ensure proper use. The drug concentrate must be diluted solely with a 5% Dextrose (glucose) solution, and no other solutions, particularly those containing chloride, may be used.

For specific populations, official guidelines define adjustments to the starting dose. The initial recommended dose is reduced to 65 mg/m^2 for adult patients with severe renal impairment (creatinine clearance <30 mL/min). No specific initial dose adjustment is required for older adults (ge 65 years).

Oxitan: Recent Clinical Evidence

Evidence for Advanced or Metastatic Colorectal Cancer

Research for Oxitan (Oxaliplatin) in advanced or metastatic colorectal cancer is based on large-scale, randomized controlled trials (RCTs). These studies monitored outcomes such as the rate of tumor shrinkage (Objective Response Rate) and time-to-event endpoints like Progression-Free Survival (PFS) and Overall Survival (OS). Findings describe patterns where the Oxitan combination was associated with a measured difference in the intervals before the disease showed further progression, compared to certain other regimens. Historical limitations include that initial regulatory reviews sometimes focused on PFS rather than consistent data for Overall Survival across all studies, and subgroup analyses indicate that OS measurements were sometimes inconsistent across certain patient subsets.

Evidence for Adjuvant Treatment of Stage III Colon Cancer

Research has explored the use of Oxitan-based regimens as an adjuvant treatment following surgery for Stage III colon cancer. This evidence comes from large, multi-center, randomized Phase III trials that tracked outcomes related to disease recurrence and long-term survival (DFS and OS). The research reported that patients receiving the Oxitan combination were observed to have a measured difference in the median time before their disease recurred, based on long-term data tracked over five, seven, and ten years. Dedicated analyses also focused on describing survival patterns for patients receiving a shorter duration of therapy compared to the standard duration.

Areas of Research Uncertainty and Study Limitations

Research is generally less extensive for other indications, such as advanced gastric and biliary tract cancers, where evidence quality varies and studies often involve smaller participant groups. Uncertainty remains regarding the optimal treatment duration for all patients with Stage III colon cancer. Furthermore, data for certain groups remain insufficient, such as patients with significant co-existing health conditions or those with specific biological characteristics of the tumor.

Common questions about Oxitan (FAQ)

---

Q: How long does the Oxitan treatment typically last?

According to official product information, the treatment duration depends on the reason for its use. For adjuvant treatment of Stage III colon cancer following surgery, treatment is typically limited to 12 cycles, which is about six months. For the treatment of advanced or metastatic colorectal cancer, treatment is generally continued until the disease progresses or if unacceptable side effects (toxicity) occur.

Q: Can Oxitan cause long-term side effects that last after treatment stops?

Regulatory documents state that patients should be aware of the possibility of persistent symptoms of peripheral sensory neuropathy (numbness or tingling) even after treatment has ended. In some cases, localized moderate symptoms have been described to persist for up to three years following the cessation of adjuvant treatment.

Q: Can Oxitan affect energy levels and cause extreme fatigue?

Yes, fatigue is one of the most frequently observed side effects. Official data classifies fatigue as a Very Common adverse reaction, meaning it is reported in more than 1 in 10 people in clinical trials.

Q: What happens if a patient misses a scheduled Oxitan treatment session?

Regulatory documents address delays in administration that may be necessary when specific side effects, such as low blood cell counts (myelosuppression), occur. If certain blood counts are too low, the treatment may be delayed until values improve, and dose adjustments may be considered by the prescribing professional. The official product information does not provide instructions for a patient-initiated, non-toxicity-related delay.

Q: Are there known effects of Oxitan on vision or hearing?

Official side effect information notes that patients may experience certain vision problems and auditory toxicity, which can include changes in hearing or hearing loss.

Q: Is Oxitan used to treat other conditions besides the main one listed?

Oxitan is officially indicated only for the treatment of advanced colorectal cancer and the adjuvant treatment of Stage III colon cancer. The use of the medicine for any other condition is not included in the primary regulatory indications.

Q: How is Oxitan different from other drugs used for the same condition?

Regulatory descriptions classify Oxitan as a third-generation platinum compound that has a unique chemical structure (the DACH ligand). Official information notes that this unique structure is important for its mechanism of action and may contribute to preventing cross-resistance with earlier platinum drugs.

Q: How long does the effect of one Oxitan dose last in the body?

The treatment schedule is set every 14 days based on pharmacological studies. Official data indicate that the platinum derivatives remain in the body in low amounts for a prolonged time. The elimination of the active platinum is described as a triphasic process with a final stage lasting approximately 16 days (391 hours).

Q: Are there special precautions for male patients regarding fathering a child while on Oxitan?

Regulatory documents state that males with female partners of reproductive potential should use effective contraception during treatment and for a specified period (such as 6 months) after the final dose. This precaution is in place due to the potential for the medicine to damage genetic material.

Q: Can Oxitan affect the liver or cause changes in liver enzyme levels?

Yes, the medicine has the potential to cause serious adverse reactions like Hepatotoxicity (liver damage). Regulatory information indicates that transient serum aminotransferase elevations (changes in liver enzyme levels) may occur, and patients may experience symptoms related to liver changes such as pain or yellowing of the skin or eyes.

Q: Does the efficacy of Oxitan treatment change over time?

Clinical research describes that the medicine's response rate may be affected in patients who have recurrence or progression after initial therapy. This suggests that the efficacy can be impacted by factors like the timing of use or the development of disease resistance.

Q: Can the administration of Oxitan be adjusted for patients with specific health issues?

Yes. Official guidelines define specific dose adjustments for managing certain adverse reactions (like neurosensory events or blood count issues) and for patients with pre-existing conditions like severe renal impairment (severely impaired kidney function).

Q: Are there different forms or strengths of Oxitan that are used?

Yes, the medicine is available as a concentrate or solution for infusion in multiple standard presentations. These typically include vials containing 50 mg, 100 mg, and 200 mg of the active ingredient.

Q: Are there any known effects of Oxitan on mental health or mood?

Some documented adverse effects listed in official documents include changes in mental state, specifically anxiety and depression. These are listed among the possible side effects.

Q: Why do some people experience a change in taste during Oxitan treatment?

Change in the ability to taste food (medically termed dysgeusia) is a documented adverse effect of the medicine listed in official product information.

Q: Is Oxitan a commonly prescribed medication?

The medicine is included on the World Health Organization's List of Essential Medicines. This designation indicates its established importance and recognized role in global standard care for its approved indications.

Storage and Disposal Requirements for Oxitan (Oxaliplatin)

The storage and disposal of Oxaliplatin are strictly governed by regulatory requirements due to its classification as a cytotoxic agent.

Storage and Stability Rules

Product State	Storage Requirements	Stability Limit
Concentrate	Store at Controlled Room Temperature (20 C to 25 C); Do Not Freeze. Must be protected from light in its original carton.	Stable until expiration date.
Diluted Solution	Can be stored for 6 hours at room temperature or up to 24 hours under refrigeration (2 C to 8 C).	Use within limit.

Special Handling and Disposal

The medicine must only be diluted with 5% Dextrose Injection, and contact with chloride-containing solutions or aluminum equipment is prohibited. As a cytotoxic drug, all unused portions must be discarded according to local, applicable special handling and disposal procedures for antineoplastic waste, and must not be disposed of in household trash or sewers.